Active Ingredient: Isoprenaline
Use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, are available.
For this indication, competent medicine agencies globally authorize below treatments:
For:
Intracardiac, 0.02 milligrams isoprenaline, one dose.
For:
Subcutaneous, 0.2 milligrams isoprenaline, one dose. Afterwards, subcutaneous, between 0.15 milligrams isoprenaline and 0.2 milligrams isoprenaline,.
Initial dose: 0.2 mg.
Subsequent administration dose range: 0.15 mg to 0.2 mg.
Subsequent dosage and method of administration depend on the ventricular rate and the rapidity with which the cardiac pacemaker can take over when the medicine is gradually withdrawn.
Isoprenaline should generally be started at the lowest recommended dose and the rate of administration gradually increased if necessary while carefully monitoring the patient.
Elderly patients may be more sensitive to the effects of sympathomimetics and lower doses may be required.
For:
Intramuscular, 0.2 milligrams isoprenaline, one dose. Afterwards, intramuscular, between 0.02 milligrams isoprenaline and 1 milligrams isoprenaline, one dose.
Initial dose: 0.2 mg.
Subsequent administration dose range: 0.02 mg to 1 mg.
Subsequent dosage and method of administration depend on the ventricular rate and the rapidity with which the cardiac pacemaker can take over when the medicine is gradually withdrawn.
Isoprenaline should generally be started at the lowest recommended dose and the rate of administration gradually increased if necessary while carefully monitoring the patient.
Elderly patients may be more sensitive to the effects of sympathomimetics and lower doses may be required.
For:
Regimen A: Intravenous, between 0.02 milligrams isoprenaline and 0.06 milligrams isoprenaline, one dose. Afterwards, intravenous, between 0.01 milligrams isoprenaline and 0.2 milligrams isoprenaline,.
Regimen B: Intravenous, 5 micrograms isoprenaline, once every minute.
| Route of Administration | Initial dose | Subsequent administration dose range* |
|---|---|---|
| Bolus intravenous injection | 0.02 mg to 0.06 mg | 0.01 mg to 0.2 mg |
| Intravenous infusion | 5 mcg/min |
* Subsequent dosage and method of administration depend on the ventricular rate and the rapidity with which the cardiac pacemaker can take over when the medicine is gradually withdrawn.
Isoprenaline should generally be started at the lowest recommended dose and the rate of administration gradually increased if necessary while carefully monitoring the patient.
Elderly patients may be more sensitive to the effects of sympathomimetics and lower doses may be required.
For:
Intravenous, 0.1 milligrams isoprenaline per kilogram of body weight, once every minute.
There are no well-controlled studies in children to establish appropriate dosing; however, the American Heart Association recommends an initial infusion rate of 0.1 mcg/kg/min, with the usual range being 0.1 mcg/kg/min to 1.0 mcg/kg/min.
Adequacy and safety of intravenous isoprenaline in children are not established. Based on published literature, the initial dose of intravenous isoprenaline used in children is not established. Based on published literature, the initial dose of intravenous isoprenaline used in children (age 7 to 19 years of age) ranges between 0.05 to 0.17 mcg/kg/min, which is increased gradually by 0.1 to 0.2 mcg/kg/min at intervals of 15 to 20 minutes, titrated to clinical response; a maximum dose ranging between 1.3 to 2.7 mcg/kg/min has been used. In children generally, post-operative cardiac patients with bradycardia require lower doses (0.029 ± 0.002 mcg/kg/min) of intravenous isoprenaline than asthma patients (0.5 ± 0.21 mcg/kg/min).
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
